Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study
Manisha AM, Shangali AR, Mfinanga SG, Mbugi EV
BMC Endocrine Disorders. 2022;22(1):175
Leggi
Breaking news
Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: perspective based on the updated evidence
Khunti K, Aroda VR, Bhatt DL, et al.
Diabetes Obes Metab. 2022, Jul 8
Leggi
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Zou X, Huang Q, Luo Y
Diabetologia. 2022 Jul 8. Online ahead of print
Leggi
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Leite AR, Angélico-Gonçalves A, Vasques-Nóvoa F, et al
Diabetes Obes Metab. 2022 Aug;24(8):1676-1680
Leggi
Obesity and weight management for prevention and treatment of type 2 diabetes
Jiang C, Cifu AS, Sam S
JAMA. Published online, 11 July 2022
Leggi
Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes
Deng X, Zhang C, Wang P, et al.
J Clin Endocrinol Metab. 2022;107(7):1888-1896.
Leggi
Socioeconomic deprivation is associated with reduced efficacy of an insulin adjustment education program for people with type 1 diabetes
Innes CWD, Henshall DE, Wilson B, et al.
Diabet Med. 2022;e14902.
Leggi
Loss of the incretin effect in type 2 diabetes: a systematic review and meta-analysis
Grespan E, Guolo A, Muscelli E, et al.
J Clin Endocrinol Metab. 2022;107(7):2092-2100.
Leggi
Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: systematic analysis of cardiorenal outcome trials in type 2 diabetes
Zaccardi F, Kloecker DE, Khunti K, Davies MJ
Diabetes Obes Metab. 2022;24(8):1598-1606.
Leggi
Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study
Ciardullo S, Rea F, Savaré L, et al.
J Clin Endocrinol Metab. 2022;107(7):e2671-e2679.
Leggi